drugset
drugset / Trial / NCT00038610

Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia

NCT00038610 ↗

Phase 2 Completed 54 enrolled M.D. Anderson Cancer Center Novartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if intensive chemotherapy, combined with imatinib mesylate (Gleevec, STI571) given for 8 courses over 6 months, followed by maintenance imatinib mesylate plus chemotherapy for 2 years, followed by imatinib mesylate indefinitely can improve Philadelphia-positive acute lymphoblastic leukemia. The safety of this treatment will also be studied.

Timeline

Start
2001-03
Primary completion
2014-07
Completion
2014-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 300 mg/m2 Intravenous
Subject Cytarabine Small molecule 100 mg Intrathecal
Subject Cytarabine Small molecule 3 g Intrathecal
Subject Dexamethasone Small molecule 40 mg Intravenous
Subject Doxorubicin Other / unclassified 50 mg/m2 Intravenous
Subject Imatinib Small molecule 600 mg Oral
Subject Methotrexate Small molecule 12 mg Intrathecal
Subject Methotrexate Small molecule 200 mg/m2 Intrathecal
Subject Methotrexate Small molecule 800 mg/m2 Intrathecal
Subject Vincristine Small molecule 2 mg Intravenous
Background 2-MERCAPTOETHANESULFONIC ACID Small molecule 600 mg/m2 Intravenous
Background G-CSF Unknown 10 ug/kg Subcutaneous

Indications

leukemia